Prostate cancer (PCa) is one of the most common malignancies in men. The curative treatment of choice is surgical removal of the tumor. Unfortunately, small tumor lesions and micrometastases are difficult to find during surgery and may be left inside the patient’s body where they ultimately can cause disease recurrence.

The aim of this project is to develop a multimodal targeting agent that contains a fluorophore/photosensitizer and a radiolabel, and is directed against the prostate-specific membrane antigen (PSMA) which is overexpressed in PCa. This agent could be used to pre-operatively visualize PCa lesions and to intra-operatively guide the surgeon in finding/resecting tumor lesions. Finally, the agent could be used for intra-operative photoimmunotherapy to specifically destroy residual tumor tissue that cannot be resected due to close vicinity to important healthy structures.